FDA Approves Pristiq For The Treatment Of Adult Patients With Major Depressive Disorder
FDA Approves Pristiq For The Treatment Of Adult Patients With Major Depressive Disorder
|
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced that the U.S. Food and Drug Administration (FDA) has approved PRISTIQ™ (desvenlafaxine), a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD). |
read more...
News entry number 4145 added on Mar 3, 2008 in the Health category.
Comenteaza
Other News in the Health category
Categorie:
Categorie:
Categorie:
Categorie:
Categorie:
Related Links
- Treatment With PEGASYS(R)/COPEGUS(TM) Provides Hope For Hepatitis C Patients Whose Infection Did Not
- Sleep Treatment Often Denied To Insomnia Patients When They Have Mental Health Conditions
- The Relationship Between Anxiety And Time To Treatment For Patients With Prostate Cancer On Surveill
- FDA Licenses 15 New Blood Typing Tests - Tests Help Ensure Safe Blood Transfusions For Patients
- FDA Approves New Uses For Evista - Drug Reduces Risk Of Invasive Breast Cancer In Postmenopausal
- Treating Arrhythmias With Sub-Zero Temps Helps Patients Lead Active, Symptom-Free Lives
- Cancer patients ask Alberta to review stance on costly drug
- Cholesterol disorder detectable in toddlers: study
- Insured, Wealthier Patients More Likely To Receive No-Cost Prescription Drug Samples From Physic
News Categories
745
523
480
347
1011
693
280
973
Top 10 News
- Texas Woman Claims to Have Found Mythical 'Chupacabra'
- Google Starts Hosting News on Website
- Wireless technology hits security budgets
- Google forced to push image in China
- Western School Board limits digital devices
- 'Spooky' science points to quantum internet
- Nuñez, gov. gamble on healthcare overhaul
- Ho-hum, the guest's another candidate
- Study Focuses On Cancer Risk In Biologic Treatment For Rheumatoid Arthritis
- Microsoft purchase of RIM nice to consider, but unlikely
Statistics
News:
News Categories:
News Read:
News Categories:
News Read:
5052
8
609
8
609